<DOC>
	<DOCNO>NCT01004224</DOCNO>
	<brief_summary>The study determine maximum tolerate dose thus recommended phase II dose schedule compound characterize safety .</brief_summary>
	<brief_title>A Dose Escalation Study Adult Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Patients histologically/cytologically confirm advanced solid tumor FGFR1 FGFR2 amplification FGFR3 mutation , effective standard anticancer treatment exist Adequate bone marrow function Adequate hepatic renal function Adequate cardiovascular function Contraception . For woman : Must surgically sterile , postmenopausal , compliant medically approve contraceptive regimen 3 month treatment period ; must negative serum urine pregnancy test must nursing . For men : Must surgically sterile compliant contraceptive regimen 3 month treatment period Patients primary CNS tumor CNS tumor involvement Patients history and/or current evidence endocrine alteration calciumphosphate homeostasis History and/or current evidence ectopic mineralization/ calcification include limited soft tissue , kidney , intestine , myocard lung exception calcify lymphnodes asymptomatic coronary calcification Current evidence corneal disorder/ keratopathy incl . limited bullous/ band keratopathy , corneal abrasion , inflammation/ulceration , keratoconjunctivitis etc. , confirm ophthalmologic examination . History current evidence cardiac arrhythmia and/or conduction abnormality Women pregnant nursing . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>lung cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>BGJ398</keyword>
	<keyword>FGFR</keyword>
	<keyword>kinase inhibitor</keyword>
	<keyword>advanced solid malignancy</keyword>
</DOC>